<DOC>
	<DOCNO>NCT01355081</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability 8-week treatment Vortioxetine ( Lu AA21004 ) , daily ( QD ) , Japanese participant major depressive disorder . The purpose study ass efficacy , safety tolerability 8-week treatment Lu AA21004 , daily ( QD ) , Japanese participant major depressive disorder .</brief_summary>
	<brief_title>Efficacy Study Vortioxetine ( Lu AA21004 ) Treatment Major Depressive Disorder</brief_title>
	<detailed_description>Lu AA21004 discover H. Lundbeck A/S , co-development H. Lundbeck A/S Takeda treatment major depressive disorder general anxiety disorder . Major depressive disorder ( MDD ) chronic , recur disease considerable morbidity general population . The estimated lifetime prevalence major depression adult population 5 25 % , approximately 2-fold high prevalence woman men . The hallmark disease depress mood , additional symptom include sleep disturbance , psychomotor agitation retardation , sexual dysfunction , weight loss , concentration difficulty delusional idea . In addition direct ill effect , MDD cause suicide job loss exerts indirect influence social economy . This study ass efficacy safety Lu AA21004 . This study consist 1-week screening period , 8-week double-blind treatment period , 4-week safety follow-up.The duration study 13 week total . Blood sample collect participant , safety follow-up contact ( visit phone call ) make 4 week completion 8-week double-blind treatment period . Subjects complete 8-week double-blind treatment period successively enter long-term extension study ( Lu AA21004/OCT-001 ; NCT01395147 ; hereinafter , OCT-001 ) , meet inclusion criterion none exclusion criterion OCT-001 study willing participate OCT-001 study . Subjects enter OCT-001 request safety follow-up completion 8-week double-blind treatment period . Lu AA21004 discover H. Lundbeck A/S , co-development H. Lundbeck A/S Takeda treatment major depressive disorder general anxiety disorder . Major depressive disorder ( MDD ) chronic , recur disease considerable morbidity general population . The estimated lifetime prevalence major depression adult population 5 25 % , approximately 2-fold high prevalence woman men . The hallmark disease depress mood , additional symptom include sleep disturbance , psychomotor agitation retardation , sexual dysfunction , weight loss , concentration difficulty delusional idea . In addition direct ill effect , MDD cause suicide job loss exerts indirect influence social economy . This study ass efficacy safety Lu AA21004 . This study consist 1-week screening period , 8-week double-blind treatment period , 4-week safety follow-up.The duration study 13 week total . Blood sample collect participant , safety follow-up contact ( visit phone call ) make 4 week completion 8-week double-blind treatment period . Subjects complete 8-week double-blind treatment period successively enter long-term extension study ( Lu AA21004/OCT-001 ; NCT01395147 ; hereinafter , OCT-001 ) , meet inclusion criterion none exclusion criterion OCT-001 study willing participate OCT-001 study . Subjects enter OCT-001 request safety follow-up completion 8-week double-blind treatment period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . The subject suffers Major Depressive Disorder ( MDD ) primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , 4th Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.2x 296.3x ) . 2 . The report duration current major depressive episode least 3 month Screening Visit . 3 . The subject MontgomeryÅsberg Depression Rating Scale ( MADRS ) total score ≥26 Screening Baseline Visits . 4 . The subject Clinical Global Impression ScaleSeverity ( CGIS ) score ≥4 Screening Baseline Visits 1 . The subject one follow condition : Any current psychiatric disorder MDD define DSMIVTR . A subject exhibit symptom anxiety eligible unless subject fulfills diagnostic criterion current anxiety disorder per DSMIVTR . Current diagnosis history manic hypomanic episode , schizophrenia psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . Current diagnosis history substancerelated disorder ( except nicotine caffeinerelated disorder ) define DSMIVTR . Presence history clinically significant neurological disorder ( include epilepsy ) . Neurodegenerative disorder ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , Huntington 's disease , etc. ) . Any DSMIVTR axis II disorder might compromise study . 2 . The current depressive symptom subject consider investigator resistant 2 adequate antidepressant treatment least 6 week duration . 3 . The subject significant risk suicide score ≥5 Item 10 ( suicidal thought ) MADRS Screening Baseline Visit , attempt suicide within 6 month prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>